mdlinx mdlinx
Latest (48) Full Text Articles (1329) Article Summary

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Zhang L et al. – Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy.

Methods

  • Patients were aged 18 years or older, were of east Asian ethnic origin, had a life expectancy of more than 12 weeks, histologically or cytologically confirmed stage IIIb or IV NSCLC, a WHO performance status of 0—2, and had completed four cycles of first-line platinum-based doublet chemotherapy without disease progression or unacceptable toxic effects.
  • Between Sept 28, 2008 and Aug 11, 2009, 296 patients were randomly assigned 1:1 to receive either gefitinib (250 mg per day orally) or placebo (orally) within 3—6 weeks after chemotherapy until progression or unacceptable toxic effects.
  • Randomisation was done via an interactive web response system with computer-generated randomisation codes.
  • Our primary endpoint was progression-free survival assessed in the intention-to-treat population.

Results
  • Progression-free survival was significantly longer with gefitinib (n=148) than with placebo (148) (median progression-free survival 4·8 months [95% CI 3·2—8·5] vs 2·6 months [1·6—2·8]; hazard ratio [HR] 0·42, 95% CI 0·33—0·55; p<0·0001).
  • Adverse events occurred more frequently with gefitinib than with placebo; the most common adverse events of any grade were rash (73 [50%] of 147 in the gefitinib group vs 14 [9%] of 148 in the placebo group), diarrhoea (37 [25%] vs 13 [9%]), and alanine aminotransferase increase (31 [21%] vs 12 [8%]).
  • The most commonly reported grade 3 or 4 adverse event was alanine aminotransferase increase (3 [2%] of 147 in the gefitinib group, none of 148 in the placebo group).
  • Ten of 147 (7%) patients given gefitinib and five of 148 (3%) patients given placebo had serious adverse events.
  • Three deaths were thought to be related to treatment with gefitinib: one from interstitial lung disease; one from lung infection; and one from pneumonia.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

Last month's top read Top Articles of 2013

1 Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy Clinical Infectious Diseases, January 30, 2014    Clinical Article

2 Prescribing of high-dose acetaminophen products discouraged Full Text U.S. Pharmacist, March 11, 2014    Free full text    Clinical Article

3 Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opinion on Pharmacotherapy, March 17, 2014    Review Article

4 New antiviral agents for the treatment of hepatitis C: ABT-450 Expert Opinion on Pharmacotherapy, March 19, 2014    Review Article
Exclusive Author Commentary

5 Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: Clinical and economic consequences PharmacoEconomics, February 11, 2014    Clinical Article

6 Collaborative practice model between cardiologists and clinical pharmacists for management of patients with cardiovascular disease in an outpatient clinic Annals of Pharmacotherapy, March 5, 2014    Review Article

7 A waste walk through clinical pharmacy: How do the seven wastes of Lean techniques apply to the practice of clinical pharmacists International Journal of Pharmacy Practice, March 27, 2014    Clinical Article

8 Effect of chronic statin treatment on vascular remodeling determined by intravascular ultrasound in patients with acute myocardial infarction The American Journal of Cardiology, March 7, 2014    Clinical Article

9 Agomelatine: A new option for treatment of depression? Expert Opinion on Pharmacotherapy, February 13, 2014    Clinical Article

10 Bedtime aspirin may be more beneficial for heart patients Full Text Pharmacy Times, December 2, 2013    Free full text    Clinical Article

11 The cardiotoxicity of cancer-related drug therapies Full Text U.S. Pharmacist, March 10, 2014    Free full text    Clinical Article

12 How long does a flu shot last? The New York Times, January 20, 2014

13 Care transitions in elderly heart failure patients: Current practices and the pharmacists role The Consultant Pharmacist, March 6, 2014    Review Article

14 The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint Nutrition, Metabolism & Cardiovascular Diseases, March 7, 2014    Clinical Article

15 Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria Journal of Clinical Pharmacy and Therapeutics, March 6, 2014    Clinical Article

16 Pediatric hypertension Full Text U.S. Pharmacist, March 10, 2014    Free full text    Clinical Article

17 Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review British Journal of Clinical Pharmacology, February 13, 2014    Evidence Based Medicine    Review Article

18 Antidepressant use and risk of coronary heart disease: Meta-analysis of observational studies British Journal of Clinical Pharmacology, March 21, 2014    Evidence Based Medicine

19 National trends in prescription drug expenditures and projections for 2014 American Journal of Health-System Pharmacy, March 4, 2014    Clinical Article

20 New cholesterol guideline: LDL goals take backseat to statins Full Text American Pharmacists Association News, November 15, 2013    Free full text    Clinical Guideline

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Other Topics in Pharmacy

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close